Clarity Pharmaceuticals Ltd
CU6.AX · ASX
Market closed2.32-0.130000 (-5.31%)
Key statistics
Previous close2.45
Open2.32
Day high2.47
Day low2.31
52-week high5.87
52-week low1.80
Market cap865.55M
Volume2.07M
Average volume2.71M
P/E ratio-10.20
Forward P/E—
EPS-0.23
Dividend yield0.00%
Market context
Why it moved
CU6.AX (Clarity Pharmaceuticals) declined sharply today following a sell signal triggered from a recent pivot top, with the overbought RSI condition and the stock retreating from the upper boundary of its trend channel prompting profit-taking and increased selling pressure.
What is happening
Recent company-specific developments and publisher coverage.
BiotechDispatch · July 16, 2026Experienced industry executive joins Clarity Pharmaceuticals boardwww.marketscreener.com · July 16, 2026Clarity Pharmaceuticals Limited Announces Appointment of Allison Rossiter as Independent Non-Executive DirectorPR Newswire · April 14, 2026Clarity signs a Commercial Manufacturing Agreement for Cu-64 SAR-bisPSMA with Nucleus RadioPharmaPR Newswire · March 25, 2026Clarity signs a large-scale Manufacturing Supply Agreement for copper-64 with TheragenicsSimply Wall Street · March 12, 2026Clarity Pharmaceuticals Valuation After AMPLIFY Trial Recruitment Surges Past Initial Target Mt Newswire · April 30, 2026Clarity Pharmaceuticals to Start Registrational Phase 3 Trial in Neuroendocrine Tumors After US FDA Meeting Mt Newswire · April 14, 2026Australian Shares Rise; Qantas Airways Raises FY26 Fuel Cost Forecast Expectation to Up to AU$3.3 Billion Mt Newswire · April 13, 2026Clarity Pharmaceuticals Enters Manufacturing Deal With Nucleus Radiopharma for Diagnostic Imaging Agent Mt Newswire · March 24, 2026Clarity Pharmaceuticals Signs Large-Scale Copper-64 Manufacturing Supply Agreement With Theragenics Mt Newswire · March 10, 2026Clarity Pharmaceuticals Hits Participant Target in Phase 3 Prostate Cancer Diagnostic Agent Trial Mt Newswire · February 27, 2026Clarity Pharmaceuticals Posts Wider Fiscal H1 Loss, Lower Income; Shares Jump 13% Mt Newswire · February 23, 2026Clarity Pharmaceuticals Says Prostate Cancer Trial Participant Achieves Undetectable Disease by Prostate-Specific Antigen; Shares Up 9% Mt Newswire · February 16, 2026Clarity Pharmaceuticals Says Diagnostic Candidate Identifies Greater Number of Lesions Per Participant in Prostate Cancer Trial